Alantos Pharmaceuticals initiates phase 1 clinical studies with lead compound for type II diabetes
18-Aug-2006 -
Alantos Pharmaceuticals announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes.
"The initiation of this clinical trial marks a ...
Beta-Cell
clinical trials
glucose
+2